IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2799
-0.0050 (-1.76%)
Oct 9, 2026, 4:00 PM EDT - Market closed
IGC Pharma Revenue
IGC Pharma had revenue of $265.00K in the quarter ending June 30, 2026, a decrease of -19.70%. This brings the company's revenue in the last twelve months to $1.10M, down -7.44% year-over-year. In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%. That makes IGC Pharma the 43,435th largest company in the world by revenue and 6,054th in the United States.
Revenue (ttm)
$1.10M
Revenue Growth
-7.44%
P/S Ratio
26.16
Revenue / Employee
$15,800
Employees
70
Market Cap
28.94M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | 4.07M | -1.04M | -20.41% |
| Mar 31, 2019 | 5.12M | 2.92M | 133.29% |
| Mar 31, 2018 | 2.19M | 1.61M | 277.86% |
| Mar 31, 2017 | 580.37K | -5.79M | -90.88% |
| Mar 31, 2016 | 6.37M | -1.31M | -17.10% |
| Mar 31, 2015 | 7.68M | 5.41M | 237.87% |
| Mar 31, 2014 | 2.27M | -5.76M | -71.69% |
| Mar 31, 2013 | 8.03M | 3.83M | 91.21% |
| Mar 31, 2012 | 4.20M | 125.63K | 3.08% |
| Mar 31, 2011 | 4.07M | -13.82M | -77.24% |
| Mar 31, 2010 | 17.90M | -17.44M | -49.35% |
| Mar 31, 2009 | 35.34M | 33.15M | 1,515.10% |
| Mar 31, 2008 | 2.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 31.52M |
| Immutep | 13.79M |
| Evaxion | 7.49M |
| Seres Therapeutics | 1.88M |
| BeyondSpring | 1.88M |
| ABVC BioPharma | 797.92K |
IGC News
- 12 days ago - IGC Pharma completes enrollment in Phase 2 CALMA trial - TheFly
- 12 days ago - IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - Accesswire
- 7 weeks ago - IGC Pharma reports Q2 EPS (3c) vs. (2c) last year - TheFly
- 7 weeks ago - IGC Pharma sees cash runway for 12 months from quarterly report filing date - TheFly
- 7 weeks ago - IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Accesswire
- 1 month ago - IGC Pharma Quarterly report: Q2 2026 - Filings
- 1 month ago - IGC Pharma Earnings release: Q2 2026 - Filings
- 2 months ago - IGC Pharma strengthens regulatory readiness of Phase 2 CALMA trial - TheFly